Related Experiment Video
Updated: Feb 12, 2026

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes
Published on: November 1, 2019
Bempedoic Acid (ETC-1002): A Current Review
Anum Saeed1, Christie M Ballantyne2
1Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, M.S. BCM285, Suite 524D, Houston, TX 77030, USA; Center for Cardiometabolic Disease Prevention, 6655 Travis Street, Suite 320, Houston, TX 77030, USA.
Abstract:
Although statins are first-line therapy for low-density lipoprotein cholesterol (LDL-C) reduction, many individuals on maximally tolerated statin therapy have elevated LDL-C. Bempedoic acid (ETC-1002) is a novel once-daily LDL-C-lowering agent in phase 3 clinical trials. In phase 1 and 2 studies, ETC-1002 was efficacious in lowering LDL-C when used as monotherapy and when added to statin and/or ezetimibe and was well tolerated in patients with statin intolerance. ETC-1002 also improved cardiometabolic risk factors. Ongoing phase 3 studies of ETC-1002 are evaluating its long-term efficacy and safety, and effects on cardiovascular events. This article discusses current evidence and future directions for ETC-1002.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Electrical Current
Current Density
Eddy Currents
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...
Displacement Current

